Department of Histology, Embryology, Pathology and Forensic, Hue University of Medicine and Pharmacy, Hue University, Vietnam.
Institute of Biomedical Research, Hue University of Medicine and Pharmacy, Hue University, Vietnam.
Asian Pac J Cancer Prev. 2020 Apr 1;21(4):1135-1142. doi: 10.31557/APJCP.2020.21.4.1135.
HER2 is the target of the therapeutic agents which are used to treat HER2-positive breast cancer. Reports have shown that the HER2 oncogene expression and its association with clinicopathological factors remain unclear in breast cancer (BC) patients. This study aimed to determine the correlation between HER2 expression and clinicalpathological characteristics of breast cancer in Vietnamese women.
Between June 2016 and August 2018, paraffin-embedded specimens from 237 patients with primary invasive breast carcinoma in Hue University Hospital and Hue Center Hospital, Hue city, Vietnam were examined for pathological features. The gene expression of HER2, ER, PR and Ki-67 were determined by immunohistochemistry (IHC). The gene amplification of Her2 was assessed by using Dual color in situ hybridization (DISH).
The most frequent histological type was invasive carcinoma of no special type (NST) with 77.35%, the highest percentage of patients with Grade II was detected (59.36%), tumor size > 2 cm accounted for 71.31% of cases, Lymph node metastases were available in 57.86% cases. Most patients were diagnosed at stage II (59.18%). The majority of patients were classified as moderate Nottingham prognostic index (54.9%). Estrogen receptor and Progesterone receptor were positive in 53.16% and 50.63%, respectively. 76.37% of cases were in high expression group of Ki-67 (≥14%). HER2 IHC 2+, 3+ were accounted for 28.69% and HER2 gene amplification was detected in 31% cases. HER2 gene amplification and/or overexpression was significantly associated with cell proliferation index Ki67. Furthermore, HER2 gene expression tended to be more frequently found in tumors with large tumor size, high grade, high stage and high Nottingham prognostic index and confirmed their prognostic independent role.
Our data indicated that HER2 gene expression was significantly correlated with cell proliferation index Ki67, but not significantly associated with another clinicopathological factors in breast cancer of Vietnamese women.
.
HER2 是用于治疗 HER2 阳性乳腺癌的治疗药物的靶点。有报道称，HER2 癌基因的表达及其与临床病理因素的关系在乳腺癌（BC）患者中仍不清楚。本研究旨在确定 HER2 表达与越南女性乳腺癌临床病理特征的相关性。
方法：2016 年 6 月至 2018 年 8 月，检测来自越南顺化 Hue 大学医院和 Hue 中心医院的 237 例原发性浸润性乳腺癌患者的石蜡包埋标本，检查病理特征。采用免疫组织化学（IHC）检测 HER2、ER、PR 和 Ki-67 的基因表达。通过双色原位杂交（DISH）评估 Her2 基因扩增。
结果：最常见的组织学类型是无特殊类型的浸润性癌（NST），占 77.35%，检测到最高比例的 II 级患者（59.36%），肿瘤大小>2cm 占 71.31%，淋巴结转移占 57.86%。大多数患者被诊断为 II 期（59.18%）。大多数患者被归类为中度诺丁汉预后指数（54.9%）。雌激素受体和孕激素受体阳性率分别为 53.16%和 50.63%。76.37%的病例为 Ki-67（≥14%）高表达组。HER2 IHC 2+、3+分别占 28.69%和 31%，HER2 基因扩增检测阳性率为 31%。HER2 基因扩增和/或过表达与细胞增殖指数 Ki67 显著相关。此外，HER2 基因表达在肿瘤体积较大、分级较高、分期较高和诺丁汉预后指数较高的肿瘤中更为常见，证实了其独立的预后作用。
结论：我们的数据表明，HER2 基因表达与细胞增殖指数 Ki67 显著相关，但与越南女性乳腺癌的其他临床病理因素无显著相关性。
